Filing Details
- Accession Number:
- 0001209191-18-038277
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-18 16:05:01
- Reporting Period:
- 2018-06-14
- Accepted Time:
- 2018-06-18 16:05:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1439222 | Agios Pharmaceuticals Inc | AGIO | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1312622 | I Kaye Foster-Cheek | C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-06-14 | 9,000 | $50.73 | 11,200 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-06-14 | 2,181 | $92.62 | 9,019 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-06-14 | 5,980 | $93.78 | 3,039 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-06-14 | 839 | $94.30 | 2,200 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2018-06-14 | 9,000 | $0.00 | 9,000 | $50.73 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2027-06-13 | No | 4 | M | Direct |
Footnotes
- This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.14 to $93.11. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.15 to $94.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.21 to $94.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018.
Billionaire Hedge Funds
